Investigator-assessed efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma: results of the BOLT 30-month analysis
John T. Lear(Salford Royal Hospital), Reinhard Dummer(University Hospital of Zurich), Michael R. Migden(The University of Texas MD Anderson Cancer Center), Ragini R. Kudchadkar, Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), A Guminski, Manisha Mone, Anne Lynn S. Chang(Stanford University), Ruth Plummer(National Health Service), Dalila Sellami(Daiichi Sankyo (United States)), P. Combemale(Centre Léon Bérard), Katie Lewis(Adelphi Group (United Kingdom)), Carmen Loquai(Johannes Gutenberg University Mainz), Martin Kaatz(SRH Wald-Klinikum Gera), Tingting Yi, Henry Castro(CytomX Therapeutics (United States)), Uwe Trefzer(Charité - Universitätsmedizin Berlin), L. Dirix, Alexander Stratigos(National and Kapodistrian University of Athens)
Melanoma Research
January 1, 2016
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k